BRCA1/2 Mutation, Breast-conserving Surgery
Conditions
Brief summary
The investigators matched BCS and mastectomy group using propensity scores and analyzed the recurrence and survival among the evenly matched patients in breast cancer patients with BRCA 1/2 mutations.
Detailed description
The purpose of study is to assess the oncologic safety of BCS in patients carrying BRCA1/2 mutations by comparing long-term outcomes with mastectomy. The investigators matched BCS and mastectomy group using propensity scores and analyzed the recurrence and survival among the evenly matched patients. By providing insights into the feasibility of BCS for patients with BRCA1/2 mutations, the investigators aim to present evidence to aid in surgical decision-making for the care of these patients.
Interventions
PROCEDUREBreast-conserving surgery
Breast-conserving surgery, also known as breast-conserving therapy or lumpectomy, is a surgical procedure used to treat breast cancer while preserving as much of the breast tissue as possible. During this procedure, the surgeon removes the cancerous tumor along with a surrounding margin of normal tissue. The goal is to remove the cancerous cells while maintaining the appearance and function of the breast as much as possible.
Sponsors
Korean Surgical Society
Korea Robot-Endoscopy Minimal Access Breast Surgery Study Group
Hanyang University Seoul Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Primary invasive breast cancer who underwent BCS or mastectomy * Received a BRCA1/2 mutation test
Exclusion criteria
* Patients with de novo metastasis * Pregnancy-associated breast cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Locoregional recurrence-free survival | Duration from diagnosis until the development of recurrence up to 10year | Recurrence in breast or chest wall and/or regional lymph nodes |
| Distant recurrence-free survival | Duration from diagnosis until the development of recurrence up to 10year | Recurrence in a distant organ |
| Recurrence-free survival | Duration from diagnosis until the development of recurrence up to 10year | Any form of disease recurrence |
Countries
South Korea
Outcome results
None listed